Peptide therapy is emerging as a logical service line extension for telehealth brands already serving GLP-1, hormone, and longevity patients, though it requires a carefully managed formulary, verified compounding partners, and physician-led evaluation to launch compliantly.
Peptides have dominated telehealth conversation for the past week, and for understandable reasons. The FDA's Pharmacy Compounding Advisory Committee concluded a two-day meeting on Friday, July 24, having reviewed seven peptides and recommended six of them for addition to the 503A bulk drug substances list. BPC-157, KPV, TB-500, and MOTS-c cleared on Thursday; epitalon and semax followed on Friday, with emideltide the only rejection. Committee members voted in favor across two days despite FDA's own scientific staff having recommended against every substance under review.
The coverage on these rulings has been extensive, and it has largely displaced the question founders are actually working through, which is commercial rather than regulatory: whether peptides represent a service line worth building, and what building one responsibly requires.
For many organizations, the answer is yes, though not for the reasons most often cited. The opportunity is less about capturing a new audience than about deepening relationships with patients a brand already serves. That distinction has meaningful implications for how a program should be designed, staffed, and sequenced.
The patients most interested in peptide therapy tend to share a recognizable profile. They are managing their health proactively rather than reactively. They are comfortable with self-administered injectables. They pay out of pocket for care. Their goals center on recovery, energy, body composition, sleep, and healthy aging. This description overlaps substantially with the patient populations telehealth brands already serve in obesity medicine, hormone health, men's health, and longevity programs.
For most operators, this means the initial demand for a peptide program is already within your existing patient base. Existing patients are frequently the ones researching these compounds, discussing them in peer communities, and in some cases sourcing them elsewhere. The commercial question is less whether demand exists and more whether it is being served within an existing clinical relationship or outside of it.
Organizations evaluating this category may find it useful to size the opportunity against their current patient base before modeling any incremental acquisition spend. In many cases, that internal figure is sufficient to justify the program on its own.
The regulatory environment for peptides has moved repeatedly since 2023, and last week's votes are unlikely to be the end of it. The committee is expected to take up additional peptides early next year, and the 2023 restrictions that put many of these substances out of reach remain under broader review.
The distinction that matters commercially is that advisory recommendations are not approvals. The committee advises; the FDA decides, and any change requires formal notice-and-comment rulemaking that has not yet concluded. Substances awaiting that process remain outside the scope of what pharmacies may legally compound, regardless of how the committee voted.
For founders, the practical takeaway is not about any particular compound. It is that formulary should be treated as a managed variable rather than a fixed product catalog. Telehealth businesses designed around a static list of substances tend to require significant rework each time classifications change. However, businesses designed with formulary as a configurable input, verified on a recurring cadence against current classifications and pharmacy sourcing documentation, absorb the same changes as routine operations.
This is an architectural decision made early or not at all. It also has direct commercial consequences. Companies confident in the compliance status of what they are offering can invest in marketing and pursue employer and enterprise channels. Organizations uncertain about it tend to throttle their own growth well before any regulator does.
Peptide programs present a clinical profile that distinguishes them from more established telehealth service lines. The evidence base varies considerably across compounds, dosing conventions have largely developed through peer communities rather than controlled trials, and combination use is common despite limited safety data on those combinations.
This is what makes clinical oversight the substance of the offering rather than a procedural layer on top of it. A prescriber evaluating a peptide request is doing work that has no equivalent elsewhere in the category. Assessing whether a compound is appropriate given the patient's history, current medications, and supplements. Selecting dose and route rather than inheriting them from a forum consensus. Ordering and interpreting labs where clinically indicated. Monitoring response across a protocol that runs for months, adjusting when warranted, and remaining available if the patient develops a reaction or wants to stop.
Published research on peptide user communities describes a folk pharmacology developing in online forums, where dosing practices and harm reduction guidance circulate peer to peer, entirely outside clinical settings. Patients arriving at a telehealth program have usually encountered that guidance already. The value a clinician adds is not filling an information vacuum. It is bringing individualized medical judgment to a decision the patient was otherwise going to make on the basis of consensus from strangers.
Taken together, these functions constitute the clinical relationship, and in an emerging category that relationship is difficult to establish quickly and difficult to replicate. It is also, for the same reasons, among the more durable competitive positions available.
One characteristic distinguishes peptides from more mature telehealth categories: the competitive field is unusually fragmented, and the fragmentation favors organizations with existing infrastructure.
A physician survey published by Sermo in mid-2026 found that patients most often obtain peptides through med spas, online retailers selling products labeled for research use, and compounding pharmacies, with med spas reported most frequently1. The finding the authors emphasize is that physicians are not the primary gatekeepers of access in this category.
Each established channel carries a structural limitation. Med spas and clinics are geographically bounded. Research-labeled online vendors operate with no clinical layer at all. What remains uncommon is a national offering that combines convenience with a genuine prescriber relationship and documented pharmacy sourcing.
That gap is unlikely to persist. Larger direct-to-consumer platforms are moving into the category, and the middle of the market will become considerably more crowded over the next several quarters. Organizations that establish clinical relationships during this period, and retain them through the regulatory changes still ahead, will be positioned differently than those entering later.
MD Integrations built peptide support inside the infrastructure our partners already use rather than as a separate system.
That includes a nationwide network of board-certified physicians licensed across all 50 states, Guam, and D.C., with every peptide request evaluated by a physician licensed in the patient's state. Intake is compound-specific rather than a general wellness questionnaire, capturing indication, prior use, concurrent medications and supplements, and contraindications relevant to the substance requested. Lab ordering and review are supported where clinically indicated.
That includes a nationwide network of board-certified physicians licensed across all 50 states, Guam, and D.C, with every peptide request evaluated by a physician licensed in the patient's state. Intake is compound-specific rather than a general wellness questionnaire, capturing indication, prior use, concurrent medications and supplements, and contraindications relevant to the substance requested. Lab ordering and review are supported where clinically indicated.
On the fulfillment side, we work with verified 503A and 503B compounding partners, with substance eligibility checked against current classifications at the point of prescribing. Every encounter produces a complete, auditable clinical record. Follow-up workflows and adverse event capture are part of the standard protocol rather than optional additions.
All of it is available through the same API our partners already integrate, with e-commerce platform support for brands operating direct-to-consumer storefronts. For organizations already running obesity medicine or hormone programs with us, adding peptides is closer to a configuration change than a new build.
If you are considering how peptide therapy would fit alongside your existing programs, MD Integrations can help you assess the clinical, operational, and compliance considerations involved, including how the opportunity sizes against your current patient base.
Talk with our team about adding a physician-powered peptide program to your offering.
Dr. Marc Serota, Founder and CEO of MD Integrations, is a quadruple board-certified physician with licensure across 45 states.
1Sermo. The peptide frontier: what 500+ physicians are seeing before regulators act. Sermo. June 4, 2026. Accessed July 27, 2026. https://www.sermo.com/barometer-reports/the-peptide-frontier-what-500-physicians-are-seeing-before-regulators-act/